NetworkNewsBreaks – Egalet Corp. (NASDAQ: EGLT) Receives New U.S. and International Patents for Guardian™ Technology

Shares of Egalet (NASDAQ: EGLT) are up 4.5% mid-day on word the company has received new U.S. and international patents for its proprietary Guardian™ Technology, bringing the number to 18 U.S. patents and 95 international patents. The United States Patent and Trademark Office (USPTO) has issued a patent covering the company’s ARYMO™ ER extended-release tablets for oral use only. It is the second U.S. patent covering ARYMO ER and offers protection through 2033 and is listed in the Orange Book. A European patent has also been issued to Egalet and offers protection of products developed using Guardian Technology. Additionally, an Australian patent was issued to the company. Both the European and Australian patents offer protection through 2030. A Canadian patent was also issued and covers Guardian Technology’s immediate-release system designed to slow the release of the active pharmaceutical ingredients in the presence of alcohol. The patent offers protection through 2030. “The newly issued patents further strengthen our ability to grow our business through the development of immediate- and extended-release products using our Guardian Technology,” Egalet executive vice president and chief operating officer Mark Strobeck, Ph.D., stated in the news release.

To view the full press release, visit: http://nnw.fm/sYup6

About Egalet

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only –CII, developed using Egalet’s proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX®(ketorolac tromethamine) Nasal Spray. Using Guardian Technology Egalet is developing a pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit www.egalet.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s